Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Lincoln Pharmaceuticals Limited (531633) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Lincoln Pharmaceuticals Limited ₹653, price ₹582, upside +12.2%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
LP
Thin data
Sep 24, 2026
Lincoln Pharmaceuticals Limited
531633 · BSEUndervaluedQuality growthThe stock appears undervalued with acceptable quality.
✓Fair value ₹653.13 · Undervalued (+12.2%)
✓Quality 60/100
✓Healthy Growth (revenue 5y +10.0 %/yr)
✓Solidly profitable · 13.8% net margin (TTM)
✓Low debt
✓0.5% dividend yield · Well covered
!Moderate moat 63/100
!Evidence only low, so the estimate is less certain
Watch Lincoln Pharmaceuticals Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹260.81 – ₹954.27 · fair‑value band ₹415.80 – ₹955.66 · the ₹582.15 price screens below the ₹653.13 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Lincoln Pharmaceuticals Limited manufactures and sells pharmaceutical products in India and internationally. It offers products in the areas of anti-infective, respiratory system, gynecology, cardio and CNS, anti-bacterial, ant-diabetic, anti-malaria, and others areas. The company also trades in pharmaceutical products.
Show more
Lincoln Pharmaceuticals Limited manufactures and sells pharmaceutical products in India and internationally. It offers products in the areas of anti-infective, respiratory system, gynecology, cardio and CNS, anti-bacterial, ant-diabetic, anti-malaria, and others areas. The company also trades in pharmaceutical products. Lincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India.
Stock analysis
Lincoln Pharmaceuticals Limited (531633) currently trades at ₹582.15, while our model-based Fair Value estimate is ₹653.13, implying the stock looks roughly 10.9% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹701.13 per share, and 18 of the 26 models we run sit above the ₹582.15 price.
Bear case: the Asset-Based group reads lowest at ₹225.01, and 8 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹415.80 (bear) to ₹955.66 (bull), the price of ₹582.15 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Lincoln Pharmaceuticals Limited reported revenue of ₹6.2B in FY2025 versus ₹4.2B in FY2021, a compound +10.1%/yr. Reported net income was ₹823M in FY2025, compounding +7.3%/yr from FY2021.
Key figures
Market cap ₹4.4B (≈ $45.9M) · P/E ratio 8.2 · P/S ratio 1.08 · EPS (TTM) ₹28.01 · Dividend yield 0.5% · Net margin 13.2% · Return on equity 17.3% · Return on assets (EBIT) 14.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 31% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −13% fair-value upside, at 12%, 531633 screens cheaper than that median.
Fair Value models
Bear ₹415.80
Fair Value ₹653.13
Bull ₹955.66
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (₹25.01 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
₹427.52
₹680.88
₹1,071
79
Growth DCF
₹429.73
₹673.40
₹1,042
77
Residual Income
₹309.46
₹363.13
₹519.55
76
All 26 models by family
DCF Models
FCF DCF
₹427.52
₹680.88
₹1,071
79
Owner Earnings
₹440.11
₹701.13
₹1,103
75
5Y Revenue Exit
₹409.38
₹666.81
₹1,002
71
5Y EBITDA Exit
₹468.27
₹780.97
₹1,155
74
5Y P/E Exit
₹553.63
₹946.44
₹1,373
70
10Y Revenue Exit
₹399.52
₹636.38
₹968.97
65
10Y EBITDA Exit
₹449.01
₹715.38
₹1,087
67
10Y P/E Exit
₹502.98
₹829.89
₹1,255
63
Earnings-Based
Graham-Dodd
₹279.98
₹1,027
₹1,386
64
Lynch FV
₹244.98
₹349.97
₹454.96
61
PEG = 1.0
₹244.98
₹349.97
₹454.96
57
EPV
₹342.19
₹394.49
₹439.61
74
Dividend Discount
Gordon GGM
₹15.83
₹31.55
₹47.77
67
DDM Multi-Stage
₹15.83
₹27.26
₹33.30
67
Multiples
P/E Multiple
₹679.36
₹905.81
₹1,132
63
P/S Multiple
₹524.96
₹699.94
₹874.93
58
P/B Multiple
₹524.96
₹699.94
₹874.93
55
EV/EBIT
₹576.01
₹764.35
₹952.69
66
EV/EBITDA
₹544.02
₹721.70
₹899.37
67
EV/Revenue
₹414.26
₹587.09
₹759.92
54
Asset-Based
NCAV (Graham)
₹167.92
₹225.01
₹335.83
54
Growth DCF
Growth DCF
₹429.73
₹673.40
₹1,042
77
Rev-Margin DCF
₹409.38
₹664.81
₹972.01
72
Economic Profit
Residual Income
₹309.46
₹363.13
₹519.55
76
ROIC Compounder
₹344.51
₹436.72
₹561.15
72
Growth Earnings
Growth-Adj P/E
₹473.13
₹675.90
₹878.67
67
Notify me when 531633 reaches fair value
Put 531633 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
60/100
Of which business quality 59 · Market factors (momentum, volatility) 46
Profitability
60
Margins and returns on capital today
Quality Growth
38
Are margins and returns improving?
Cashflow
58
Earnings quality: real cash, not paper profit
Fin. Strength
65
Balance sheet, leverage, solvency risk
Investment
48
Disciplined investing over empire-building
Low Volatility
56
Calm price path (market factor)
Momentum
43
Price trend over the last 3–12 months (market factor)
52W Momentum
42
Distance to the 52-week high (market factor)
Net Issuance
82
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
91/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+7.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
Start year 2020 (pandemic). Over 10 years: +8.9% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+10.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.8%
Dividend (yield on the price)0.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 14%
Watch 531633, get fair value alerts →
Compare Lincoln Pharmaceuticals Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drug Manufacturers - Major” was too small, so the broader sector is used.)Health Care · 2455 stocks
Beats the sector median on 11/12 measures
Overall it ranks above its sector peers.
Valuation Multiplesvs Health Care median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Drug Manufacturers - Major stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Makers Laboratories Limited 506919 | ₹188.25 | ₹105.20 | −44% |
| COLINZ COLINZ | ₹76.20 | ₹34.72 | −54% |
| Eli Lilly and Company LLY | $1,157 | $749.08 | −35% |
| Johnson & Johnson, JNJ | $264.74 | $168.85 | −36% |
| AbbVie Inc ABBV | $261.59 | $259.62 | −1% |
| Roche Holding RO | CHF 375.20 | CHF 326.56 | −13% |
| Merck & Co MRK | $143.81 | $129.26 | −10% |
| UnitedHealth Group UNH | $367.08 | $295.49 | −20% |
| Novartis AG NOVN | CHF 118.06 | CHF 121.90 | +3% |
| Thermo Fisher Scientific Inc TMO | $675.05 | $686.04 | +2% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Lincoln Pharmaceuticals Limited (531633) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹653.13 versus a price of ₹582.15, about +12% upside (undervalued).
What is the fair value of 531633?
Our model-based fair value for Lincoln Pharmaceuticals Limited is ₹653.13 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹582.15.
What is the quality score of 531633?
Lincoln Pharmaceuticals Limited has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lincoln Pharmaceuticals Limited (531633)?
Our model-based price target is the fair value of ₹653.13 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario ₹415.80, optimistic scenario ₹955.66. It is a calculation from audited fundamentals, not an analyst target.
What is the Lincoln Pharmaceuticals Limited stock forecast for 2026?
Our models put fair value at ₹653.13, about +12% upside versus a price of ₹582.15 (undervalued). Cautious scenario ₹415.80, optimistic scenario ₹955.66. The calculation is refreshed regularly with new filings.
What is the revenue of Lincoln Pharmaceuticals Limited (531633)?
Lincoln Pharmaceuticals Limited reported trailing-twelve-month revenue of about ₹4.1B (latest available figure, as of Sep 24, 2026).
Does Lincoln Pharmaceuticals Limited pay a dividend?
Lincoln Pharmaceuticals Limited currently shows a dividend yield of about 0.52% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Lincoln Pharmaceuticals Limited (531633)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lincoln Pharmaceuticals Limited it is ₹653.13 per share (as of Sep 24, 2026), against a price of ₹582.15. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Lincoln Pharmaceuticals Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 531633 trades below its calculated fair value: price ₹582.15, fair value ₹653.13, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 531633?
No. The price is what the market pays today (₹582.15); the fair value is what the company's own numbers justify (₹653.13). For Lincoln Pharmaceuticals Limited the two are ₹70.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lincoln Pharmaceuticals Limited worth?
The market values Lincoln Pharmaceuticals Limited at about ₹4.4B (market capitalisation, as of Sep 24, 2026). Per share that is ₹582.15; our models calculate a fair value of ₹653.13 per share.
What do the bullish and bearish scenarios say about 531633?
Our models span a range for Lincoln Pharmaceuticals Limited: cautious scenario ₹415.80, base ₹653.13, optimistic ₹955.66 per share (as of Sep 24, 2026, price ₹582.15). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 531633?
Lincoln Pharmaceuticals Limited trades at a price-to-earnings ratio of 8.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹653.13 is built from several models across several years. Other multiples: P/B 0.7, P/S 1.1, EV/EBITDA 5.7.
How solid is the balance sheet of Lincoln Pharmaceuticals Limited (531633)?
Balance-sheet figures for Lincoln Pharmaceuticals Limited (as of Sep 24, 2026): return on equity 17.3%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 531633 from its 52-week high?
Lincoln Pharmaceuticals Limited trades at ₹582.15, about 23% below its 52-week high of ₹758.35 and 31% above the low of ₹445.55 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹653.13 is for.
Which stocks are comparable to Lincoln Pharmaceuticals Limited?
From the same area (Healthcare) we also value Makers Laboratories Limited, COLINZ, Eli Lilly and Company, Johnson & Johnson,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lincoln Pharmaceuticals Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹582.15, calculated fair value ₹653.13 (+12%), Quality Score 60/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 531633 calculated?
We run Lincoln Pharmaceuticals Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹653.13, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Lincoln Pharmaceuticals Limited currently trades 11 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lincoln Pharmaceuticals Limited (531633)?
The closing price on Oct 1, 2026 was ₹582.15. Our model-based fair value is ₹653.13, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lincoln Pharmaceuticals Limited right now?
A fairly wide model range (₹415.80 to ₹955.66) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Lincoln Pharmaceuticals Limited
How large is the market capitalisation of Lincoln Pharmaceuticals Limited (531633)?
The market capitalisation of Lincoln Pharmaceuticals Limited is ₹4.4B (≈ $45.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lincoln Pharmaceuticals Limited (531633)?
The price-to-sales ratio of Lincoln Pharmaceuticals Limited is 1.08 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lincoln Pharmaceuticals Limited (531633)?
Earnings per share at Lincoln Pharmaceuticals Limited are ₹28.01 (price ÷ EPS = P/E 8.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Lincoln Pharmaceuticals Limited (531633)?
The dividend yield of Lincoln Pharmaceuticals Limited is 0.5% (payout 10.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Lincoln Pharmaceuticals Limited (531633)?
The net margin of Lincoln Pharmaceuticals Limited is 13.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lincoln Pharmaceuticals Limited (531633)?
The return on equity (ROE) of Lincoln Pharmaceuticals Limited is 17.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lincoln Pharmaceuticals Limited (531633)?
On an EBIT basis the return on assets of Lincoln Pharmaceuticals Limited is 14.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lincoln Pharmaceuticals Limited (531633)?
The operating margin of Lincoln Pharmaceuticals Limited is 16.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lincoln Pharmaceuticals Limited (531633)?
Revenue at Lincoln Pharmaceuticals Limited is growing +11.9% versus a year earlier (3y avg +9.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Lincoln Pharmaceuticals Limited (531633)?
Earnings per share at Lincoln Pharmaceuticals Limited are growing +10.6% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Lincoln Pharmaceuticals Limited in the live analysis
One click puts Lincoln Pharmaceuticals Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.